Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : High Tolerance Plasticity -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (13282)	4/15/2002 8:36:24 PM
From: JHP	Read Replies (1) \| Respond to of 23153

>>Interesting... doesn't CELG own Thalidomde now and ENMD recieves potential royalties??? << No make sure you read the last sentance. from:http://biz.yahoo.com/prnews/020415/dcm013_1.html Dr. John Holaday, EntreMed Chairman and CEO said, ``Today's ENMD 0995 findings validate our decision last summer to monetize our future asset from the sale of thalidomide (Thalomid®) and to commit further resources to a more selective, less toxic derivative of thalidomide. Further, the funds we received from the sale of thalidomide have enabled us to invest further in our pipeline of promising new angiogenesis inhibitors and to continue to move our three lead drug candidates -- Endostatin, Panzem(TM) and Angiostatin -- through the clinic.'' In 1998, EntreMed licensed thalidomide for angiogenesis-related diseases to Celgene Corporation in exchange for royalty payments that totaled $5.6 million. In August 2001, EntreMed sold the future royalties from thalidomide for $24.3 million to Royalty Pharma AG, a Swiss stock corporation.*** Thalidomide analogs under development at EntreMed since 1994, including ENMD 0995, were specifically excluded from the Celgene licensing agreement.